NCT06723041 Acupressure for the Reduction of Anxiety in Patients Receiving Cancer-Directed Therapy
| NCT ID | NCT06723041 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Hematopoietic and Lymphatic System Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 78 participants |
| Start Date | 2024-12-11 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 78 participants in total. It began in 2024-12-11 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinicaI trial is being done to determine if acupressure is helpful to reduce anxiety related to chemotherapy, compared with "sham" (or placebo) acupressure in patients with cancer. Anxiety, experienced by many patients with cancer, can be related to chemotherapy and may contribute to other symptoms, such as nausea and poor quality of life. Some patients diagnosed with cancer express interest in non-medicine ways to manage symptoms. Acupressure is the application of non-invasive finger pressure along energy points throughout the body in order to relieve pain and induce a feeling of well-being. Previous research has shown that acupressure can help both adults and children with their anxiety in certain situations, such as after surgery. Patients can be taught how to do the acupressure on themselves, making this an intervention that can be done anywhere. Acupressure is well tolerated with minimal reports of adverse reactions. Undergoing acupressure may be effective in reducing anxiety in cancer patients receiving chemotherapy.
Eligibility Criteria
Inclusion Criteria: * NURSE-LED INTERVENTION: Age \>= 18 years and be diagnosed with cancer * NURSE-LED INTERVENTION: Undergoing systemic, antineoplastic therapy * NURSE-LED INTERVENTION: Ability to provide oral consent * NURSE-LED INTERVENTION: Willingness to undergo a nurse-led acupressure intervention * NURSE-LED INTERVENTION: Willingness and ability to complete pre- and post-intervention questionnaires in English * NURSE-LED INTERVENTION: Report acute anxiety as a 5 or higher on a scale for 0 (no anxiety) to 10 (severe anxiety) * SELF-ADMINISTRATION INTERVENTION: Age \>= 18 years and be diagnosed with cancer * SELF-ADMINISTRATION INTERVENTION: Undergoing systemic, antineoplastic therapy * SELF-ADMINISTRATION INTERVENTION: Ability to provide oral consent * SELF-ADMINISTRATION INTERVENTION: Willingness to undergo a nurse-led acupressure intervention * SELF-ADMINISTRATION INTERVENTION: Willingness and ability to complete pre- and post-intervention questionnaires in English * SELF-ADMINISTRATION INTERVENTION: Report acute anxiety as a 5 or higher on a scale for 0 (no anxiety) to 10 (severe anxiety) * SELF-ADMINISTRATION INTERVENTION: Reports 2+/day anxiety episodes at home * SELF-ADMINISTRATION INTERVENTION: Interested in learning self-administered acupressure Exclusion Criteria: * Prior experiences with acupressure, or training in acupressure points
Contact & Investigator
Elizabeth Cathcart-Rake, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic in Rochester
Frequently Asked Questions
Who can join the NCT06723041 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematopoietic and Lymphatic System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06723041 currently recruiting?
Yes, NCT06723041 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.
Where is the NCT06723041 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06723041 clinical trial?
NCT06723041 is sponsored by Mayo Clinic. The principal investigator is Elizabeth Cathcart-Rake, MD at Mayo Clinic in Rochester. The trial plans to enroll 78 participants.